Brief: Nicox: Results From NCX 4251 Phase 2b Mississippi Blepharitis Trial Did Not Meet Primary Or Secondary Efficacy Endpoints

Nicox SA

23/09/2021 08:08

Sept 23 (Reuters) - Nicox SA  NCOX.PA :
    * ANNOUNCES RESULTS FROM THE NCX 4251 PHASE 2B MISSISSIPPI
BLEPHARITIS TRIAL
    * TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS
    * PLEASED TO SEE THAT THERE IS A SIGNAL OF EFFICACY IN
COMPOSITE
SCORE OF SIGNS AND SYMPTOMS OF BLEPHARITIS
    * TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS
    * NEXT STEPS AND TIMELINES IN DEVELOPMENT OF NCX 4251 WILL
BE
ANNOUNCED FOLLOWING A MEETING WITH U.S. FOOD AND DRUG
ADMINISTRATION, EXPECTED TO TAKE PLACE AT BEGINNING OF 2022
    * A SIGNAL OF NCX 4251'S POTENTIAL EFFICACY WAS SEEN IN
TRIAL WITH
NCX 4251 0.1% SHOWING A NUMERICAL IMPROVEMENT OVER PLACEBO IN
PRIMARY OUTCOME MEASURE
    * BLEPHARITIS IS A COMMON EYE CONDITION CHARACTERIZED BY
EYELID
INFLAMMATION
    * NCX 4251 ALSO SHOWED A STATISTICALLY SIGNIFICANT
DIFFERENCE
AGAINST PLACEBO IN EXPLORATORY ENDPOINT
    * NCX 4251 WAS FOUND TO BE SAFE AND WELL-TOLERATED OVER 14
DAYS'
TREATMENT
    * ALL OF ADVERSE EVENTS FOR NCX 4251 TREATMENT ARM WERE MILD
    * THERE WERE NO DISCONTINUATIONS IN STUDY DUE TO AN ADVERSE
EVENT

Source text for Eikon:  ID:nGNX1YC0Z2 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))